DOCSLIB.ORG

The Alterations of Cytokeratin and Vimentin Protein Expressions In

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Alterations of Cytokeratin and Vimentin Protein Expressions In Li et al. BMC Cancer (2018) 18:356 https://doi.org/10.1186/s12885-018-4301-1 RESEARCH ARTICLE Open Access The alterations of cytokeratin and vimentin protein expressions in primary esophageal spindle cell carcinoma Xin Min Li1, Xin Song1, Xue Ke Zhao1, Shou Jia Hu1, Rang Cheng1, Shuang Lv1,2, Dan Feng Du1,3, Xiang Yang Zhang1, Jian Liang Lu1,2, Jian Wei Ku1,4, Dong Yun Zhang1,5, Yao Zhang6, Zong Min Fan1 and Li Dong Wang1* Abstract Background: The accumulated evidence has indicated the diagnostic role of cytokeratin (CK) and vimentin protein immunoassay in primary esophageal spindle cell carcinoma (PESC), which is a rare malignant tumor with epithelial and spindle components. However, it is largely unknown for the expression of CK and vimentin in pathological changes and prognosis of PESC. Methods: Eighty-two PESC patients were identified from the esophageal and gastric cardia cancer database established by Henan Key Laboratory for Esophageal Cancer Research of Zhengzhou University. We retrospectively evaluated CK and vimentin protein expressions in PESC. Clinicopathological features were examined by means of univariate and multivariate survival analyses. Furthermore, the co-expression value of cytokeratin and vimentin was analyzed by receiver operating characteristic (ROC) curve. Results: The positive pan-cytokeratins AE1/AE3 (AE1/AE3 for short) staining was chiefly observed in cytoplasm of epithelial component tumor cells, with a positive detection rate of 85.4% (70/82). Interestingly, 19 cases showed AE1/ AE3 positive staining both in epithelial and spindle components (23.2%). However, AE1/AE3 expression was not observed with any significant association with age, gender, tumor location, gross appearance, lymph node metastasis and TNM stage. Furthermore, AE1/AE3 protein expression does not show any effect on survival. Similar results were observed for vimentin immunoassay. However, in comparison with a single protein, the predictive power of AE1/AE3 and vimentin proteins signature was increased apparently than with single signature [0.75 (95% CI = 0.68–0.82) with single protein v.s. 0.89 (95% CI = 0.85–0.94) with AE1/AE3 and vimentin proteins]. The 1-, 3-, 5- and 7-year survival rates for PESC patients in this study were 79.3%, 46.3%, 28.0% and 15.9%, respectively. Multivariate analysis demonstrated age and TNM stage were independent prognostic factors for overall survival (P = 0.036 and 0.003, respectively). It is noteworthy that only 17.1% patients had a PESC accurate diagnosis by biopsy pathology before surgery (14/82). 72.4% PESC patients with biopsy pathology before surgery had been diagnosed as squamous cell carcinoma. Conclusion: The present study demonstrates that cytokeratin and vimentin protein immunoassay is a useful biomarker for PESC accurate diagnosis, but not prognosis. The co-expression of cytokeratin and vimentin in both epithelial and spindle components suggest the possibility of single clone origination for PESC. Keywords: Esophagus, Spindle cell carcinoma, Immunohistochemical staining, Cytokeratin, Vimentin * Correspondence: [email protected] 1Henan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, 40 Daxue Road, Zhengzhou, Henan 450052, People’s Republic of China Full list of author information is available at the end of the article © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Li et al. BMC Cancer (2018) 18:356 Page 2 of 12 Table 1 Clinical characteristics of 82 PESC patients n (%) No. of case of examination (%) Age < 60 years 26 (31.7) ≥ 60 years 56 (68.3) Gender Male 57 (69.5) Female 25 (30.5) Family history Positive 18 (22.0) Negative 64 (78.0) Smoking Yes 41 (50.0) Fig. 1 Histological examination (100×) revealed two No 41 (50.0) tumor components Alcohol Yes 36 (43.9) immunohistochemical features for CK and vimentin in No 46 (56.1) PESC accurate diagnosis and prognosis prediction. Tumor location In the present study, we retrospectively analyzed the Uppera 3 (3.7) CK and vimentin immunoreactivity and their possible Middle 54 (65.9) roles in accurate diagnosis and prognosis on 82 cases Lower 25 (30.4) with PSEC, which were retrieved from our esophageal Gross appearance cancer database from 1973 to 2015. Polypoid 69 (84.1) Methods Ulcerative 8 (9.8) Patients Infiltrating 5 (6.1) The two hundreds and eighty-six PESC patients were Lymph node metastasis identified from the esophageal and gastric cardia cancer Yes 23 (28.0) database (with a total of 500,000 patients) established by No 59 (72.0) Henan Key Laboratory for Esophageal Cancer Research, the First Affiliated Hospital of Zhengzhou University TNM stage from 1973 to 2015 [6]. Based on the criteria of more I 29 (35.4) than 5 year follow-up after surgical treatment and II 37 (45.1) III 16 (19.5) IV 0 (0.0) aThere was one patient whose tumor location was in cervical segment Background The primary esophageal spindle cell carcinoma (PESC), which has also been referred to as carcinosarcoma, sar- comatoid carcinoma, pseudosarcoma, pseudosarcoma- tous carcinoma, or polypoid carcinoma in literature, has been classified as a subtype of esophageal squamous cell carcinoma by WHO in 2010 [1]. Histopathologically, PESC is characterized by mixed two components, i.e., epithelial and spindle. Although the histogenesis of these two different components remains largely unknown, the accumulated evidence from many case reports has indi- cated the differential role of cytokeratin (CK) and vimen- Fig. 2 The protein expressions of AE1/AE3 in PESC tissues by tin protein immunoassay in PESC diagnosis [2–5]. immunohistochemistry (100×). The positive immunostaining of AE1/ AE3 was localized in cell cytoplasm of epithelial component However, it has not been well characterized in terms of Li et al. BMC Cancer (2018) 18:356 Page 3 of 12 Table 2 The expression rate of AE1/AE3 protein in PESC Number Expression rate of χ2 P AE1/AE3 protein (%) Positive(n = 70) Negative(n = 12) Age < 60 years 26 19 (73.1) 7 (26.9) 3.28 0.070 ≥ 60 years 56 51 (91.1) 5 (8.9) Gender Male 57 48 (84.2) 9 (15.8) 0.01 0.914 Female 25 22 (88.0) 3 (12.0) Family history Positive 18 16 (88.9) 2 (11.1) 0.01 0.919 Negative 64 54 (84.3) 10 (15.7) Smoking Yes 41 34 (82.9) 7 (17.1) 0.10 0.755 No 41 36 (87.8) 5 (12.2) Alcohol Yes 36 30 (83.3) 6 (16.7) 0.21 0.654 No 46 40 (87.0) 6 (13.0) Tumor location Upper 3 2 (66.7) 1 (33.3) 1.48 0.580 Middle 54 46 (85.2) 8 (14.8) Lower 25 22 (88.0) 3 (12.0) Gross appearance Polypoid 69 59 (85.5) 10 (14.5) 1.30 0.660 Ulcerative 8 6 (75.0) 2 (25.0) Infiltrating 5 5 (100.0) 0 (0.0) Lymph node metastasis Yes 23 21 (91.3) 2 (8.7) 0.36 0.547 No 59 49 (83.1) 10 (16.9) TNM stage I 29 27 (93.1) 2 (6.9) 4.40 0.121 II 37 28 (75.7) 9 (24.3) III 16 15 (93.8) 1 (6.2) IV 0 0 (0.0) 0 (0.0) detailed clinicohistopathological findings, eighty-two cohort was 50.1 months (range, 4.1–123.5 months). The PSEC patients were finally enrolled in this study, includ- success follow-up rate was 94.2%. Informed consent was ing 57 males with a mean age of 61.8 ± 8.8 years and 25 obtained from all these patients before taking part in our females with a mean age of 64.1 ± 6.6 years. All the study. This study was approved by the Ethical Committee PESC patients were performed surgical treatment and of Zhengzhou University (No.16047). did not receive any radio- or chemo-therapy before sur- gery. The clinicopathological characteristics of the 82 pa- Surgical specimen preparation and tients were summarized in Table 1. The gross appearance immunohistochemistry of PESC was classified into three types, i.e., polypoid, ul- The entire surgical specimen was routinely formalin- cerative and infiltrating [7]. Overall survival (OS) time was fixed, paraffin-embedded and H&E stained for histo- calculated from the day of esophagectomy to death or to pathological diagnosis and immunohistochenistry assay. the last follow-up. The median follow-up of the entire The immunoreactivty for pan-cytokeratins AE1/AE3 Li et al. BMC Cancer (2018) 18:356 Page 4 of 12 Table 3 The expression of AE1/AE3 protein in different components of PESC Number Expression rate of AE1/ Positive in epithelial Positive in spindle Positive in both of epithelial and χ2 P AE3 protein (%) component (%) component (%) spindle components (%) Age < 26 19 (73.1) 19 (73.1) 6 (23.1) 6 (23.1) 0.24 0.888 60 years ≥ 56 51 (91.1) 51 (91.1) 13 (23.2) 13 (23.2) 60 years Gender Male 57 48 (84.2) 48 (84.2) 13 (22.8) 13 (22.8) 0.00 1.000 Female 25 22 (88.0) 22 (88.0) 6 (24.0) 6 (24.0) Family history Positive 18 16 (88.9) 16 (88.9) 1 (5.6) 1 (5.6) 5.777 0.118 64 54 (84.3) 54 (84.3) 18 (28.1) 18 (28.1) Negative Smoking Yes 41 34 (82.9) 34 (82.9) 10 (24.4) 10 (24.4) 0.197 0.978 No 41 36 (87.8) 36 (87.8) 9 (22.0) 9 (22.0) Alcohol Yes 36 30 (83.3) 30 (83.3) 10 (27.8) 10 (27.8) 1.154 0.764 No 46 40 (87.0) 40 (87.0) 9 (19.6) 9 (19.6) Tumor location Upper 3 2 (66.7) 2 (66.7) 1 (33.3) 1 (33.3) 6.42 0.126 Middle 54 46 (85.2) 46 (85.2) 16 (29.6) 16 (29.6) Lower 25 22 (88.0) 22 (88.0) 2 (8.0) 2 (8.0) Gross appearance 69 59 (85.5) 59 (85.5) 15 (21.7) 15 (21.7) 3.22 0.794 Polypoid 8 6 (75.0) 6 (75.0) 1 (12.5) 1 (12.5) Ulcerative 5 5 (100.0) 5 (100.0) 3 (60.0) 3 (60.0) Infiltrating Lymph node metastasis Yes 23 21 (91.3) 21 (91.3) 8 (34.8) 8 (34.8) 1.60 0.449 No 59 49 (83.1) 49 (83.1) 11 (18.6) 11 (18.6) TNM stage I 29 27 (93.1) 27 (93.1) 3 (10.3) 3 (10.3) 6.71 0.146 II 37 28 (75.7) 28 (75.7) 9 (24.3) 9 (24.3) III 16 15 (93.8) 15 (93.8) 7 (43.8) 7 (43.8) IV 0 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) (AE1/AE3 for short) and CK5/6, chiefly in epithelial (1:100 dilutions, Gene Tech, USA).
Load more

Recommended publications
  • Introduction Aim Method Conclusions Acknowledgements References 1 2
    Tenofovir Alafenamide Used Throughout Pregnancy Q-L Zeng1, G-M Li2, Y-H Feng3, Z-Q Li1, G-F Zhang4, J-H Xu5, Z-M Chen6, G-L in Chinese Active Chronic Hepatitis B Mothers: A Cui7, Y-H Zhou8 and Z-J Yu1 Multicenter Prospective Study 1 Department of Infectious Diseases and Hepatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China; 2 Department of Hepatology, The Sixth People’s Hospital of Zhengzhou City, Zhengzhou, Henan, China; 3 Department of Hepatology, The Sixth People’s Hospital of Kaifeng City, Kaifeng, Henan, China; 4 Department of Infectious Scan to Diseases, The First Affiliated Hospital of Nanyang Medical College, Nanyang, Henan, China; 5 Department of Hepatology, The download the poster Introduction Fifth People’s Hospital of Anyang City, Anyang, Henan, China; 6 Department of Obstetrics, The First Affiliated Hospital of 1 Zhengzhou University, Zhengzhou, Henan, China; 7 Department of Clinical Laboratory, The First Affiliated Hospital of Data on tenofovir alafenamide (TAF) therapy for pregnant Zhengzhou University, Zhengzhou, Henan, China; and 8 Department of Experimental Medicine and Jiangsu Key Laboratory women with active chronic hepatitis B (CHB) are lacking. for Molecular Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China. 2 Aim 4 Results To investigate the safety and effectiveness of TAF administration Among 1516 assessed mothers, 60 were in active CHB mothers and their infants. enrolled. At TAF initiation, the mean age, gestational age, alanine aminotransferase, and Method 3 HBV DNA levels were 29.6 (± 4.6) years, 1.0 (± In this multicenter prospective study, active CHB mothers treated with TAF were enrolled, infants received standard 13.7) weeks, 112.5 (± 93.2) U/L, and 4.6 (± 3.5) immunoprophylaxis, and all were followed until at least log10 IU/ml, respectively.
    [Show full text]
  • The Spreading of Christianity and the Introduction of Modern Architecture in Shannxi, China (1840-1949)
    Escuela Técnica Superior de Arquitectura de Madrid Programa de doctorado en Concervación y Restauración del Patrimonio Architectónico The Spreading of Christianity and the introduction of Modern Architecture in Shannxi, China (1840-1949) Christian churches and traditional Chinese architecture Author: Shan HUANG (Architect) Director: Antonio LOPERA (Doctor, Arquitecto) 2014 Tribunal nombrado por el Magfco. y Excmo. Sr. Rector de la Universidad Politécnica de Madrid, el día de de 20 . Presidente: Vocal: Vocal: Vocal: Secretario: Suplente: Suplente: Realizado el acto de defensa y lectura de la Tesis el día de de 20 en la Escuela Técnica Superior de Arquitectura de Madrid. Calificación:………………………………. El PRESIDENTE LOS VOCALES EL SECRETARIO Index Index Abstract Resumen Introduction General Background........................................................................................... 1 A) Definition of the Concepts ................................................................ 3 B) Research Background........................................................................ 4 C) Significance and Objects of the Study .......................................... 6 D) Research Methodology ...................................................................... 8 CHAPTER 1 Introduction to Chinese traditional architecture 1.1 The concept of traditional Chinese architecture ......................... 13 1.2 Main characteristics of the traditional Chinese architecture .... 14 1.2.1 Wood was used as the main construction materials ........ 14 1.2.2
    [Show full text]
  • Characterization of 500 Chinese Patients with Cervical Esophageal Cancer by Clinicopathological and Treatment Outcomes
    Cancer Biol Med 2020. doi: 10.20892/j.issn.2095-3941.2019.0268 ORIGINAL ARTICLE Characterization of 500 Chinese patients with cervical esophageal cancer by clinicopathological and treatment outcomes Peinan Chen1, Xueke Zhao1, Fuyou Zhou1,2, Xin Song1, Shoujia Hu1, Yan Jin1,3, Xianzeng Wang4, Xuena Han1, Zongmin Fan1, Ran Wang1, Bei Li1, Wenli Han1,5, Panpan Wang1, Jilin Li6, Lixin Wan7, Liguo Zhang8, Qide Bao9, Fubao Chang10, Yanru Qin1,11, Zhiwei Chang1,11, Jianwei Ku12, Haijun Yang13, Ling Yuan14, Jingli Ren15, Xuemin Li16, Lidong Wang1 1State Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China;2 Department of Thoracic Surgery, Anyang Tumor Hospital, Anyang 455000, China; 3Department of Histology and Embryology, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang 453000, China; 4Department of Thoracic Surgery, Linzhou People’s Hospital, Linzhou 456550, China; 5Department of Pathology and Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450000, China; 6Department of Pathology, Linzhou Esophageal Cancer Hospital, Linzhou 456550, China; 7Department of Oncology, Nanyang Central Hospital, Nanyang 473000, China; 8Department of Thoracic Surgery, Xinxiang Central Hospital, Xinxiang 453000, China; 9Department of Oncology, Anyang District Hospital, Anyang 455000, China; 10Department of Thoracic Surgery, Linzhou Center Hospital, Linzhou 456550, China;
    [Show full text]
  • 1 Please Read These Instructions Carefully
    PLEASE READ THESE INSTRUCTIONS CAREFULLY. MISTAKES IN YOUR CSC APPLICATION COULD LEAD TO YOUR APPLICATION BEING REJECTED. Visit http://studyinchina.csc.edu.cn/#/login to CREATE AN ACCOUNT. • The online application works best with Firefox or Internet Explorer (11.0). Menu selection functions may not work with other browsers. • The online application is only available in Chinese and English. 1 • Please read this page carefully before clicking on the “Application online” tab to start your application. 2 • CLIC on the Edit Personal Details button. 3 • Fill out your personal information accurately. o Make sure to have a valid passport at the time of your application. o Use the name and date of birth that are on your passport. Use the name on your passport for all correspondences with the CLIC office or Chinese institutions. o List Canadian as your Nationality, even if you have dual citizenship. Only Canadian citizens are eligible for CLIC support. o Enter the mailing address for where you want your admission documents to be sent under Permanent Address. Leave Current Address blank. o Once you have completed this section click Verify and Save. 4 • Fill out your Education and Employment History accurately. o For Highest Education enter your current degree studies. o Once you have completed this section, click Verify and Save. 5 • Provide the contact information of the host Chinese university. o The contact information for summer programs is available on the CLIC website in the Program Finder. o For exchange programs, please contact your home university international office to get your host university contact information (http://clicstudyinchina.com/contact-us/).
    [Show full text]
  • Accepted Manuscript These Authors Contributed Equally As Joint Senior Authors
    Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study Qing-Lei Zeng,1,a, * Zu-Jiang Yu,1, a, * Fanpu Ji,2,a Guang-Ming Li,3 Guo-Fan Zhang,4 Jiang-Hai Xu,5 Downloaded from https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1939/6062485 by Jules Levin on 10 January 2021 Zhi-Min Chen,6 Guang-Lin Cui,7 Wei Li,8 Da-Wei Zhang,9 Juan Li,1 Jun Lv,1 Zhi-Qin Li,1 Hong-Xia Liang,1 Chang-Yu Sun,1 Ya-Jie Pan,1 Yan-Min Liu,1 and Fu-Sheng Wang9,* 1Department of Infectious Diseases and Hepatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China, 2Department of Infectious Diseases, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China, 3Department of Hepatology, The Sixth People’s Hospital of Zhengzhou City, Zhengzhou, Henan, China, 4Department of Infectious Diseases, The First Affiliated Hospital of Nanyang Medical College, Nanyang, Henan, China, 5Department of Hepatology, The Fifth People’s Hospital of Anyang City, Anyang, Henan, China, 6Department of Obstetrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China, 7Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China, 8Department of Infectious Diseases, Henan Provincial People’s Hospital, Zhengzhou, Henan, China, and 9Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China aThese authors contributed equally as joint first authors. * Accepted Manuscript These authors contributed equally as joint senior authors.
    [Show full text]
  • Online Supplement
    Clinical characteristics and outcomes of hospitalized patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): A Nationwide Analysis of China Online Supplement Figure S1. The flowchart of cohort establishment As of February 15th, 2020, a total of 68,500 laboratory-confirmed cases have been identified in China. The largest percentage (82.12%) of cases were diagnosed in Hubei province (56,249 patients). The percentage of cases with severe pneumonia in Hubei province (21.20%) was higher than that outside of Hubei province (10.45%). The mortality was also higher in Hubei province (2.84% vs. 0.56%). (Figure S3). Figure S2 shows the change of mortality rate in Hubei province, regions outside of Hubei province and the overall population who had laboratory-confirmed COVID-19. Figure S1. Trends of daily mortality stratified by the geographic location where patients with COVID-19 were diagnosed and managed. COVID-19: coronavirus disease 2019 1 Figure S2. Severe and deaths cases in China, in Hubei and outside Hubei province as of Feb 15th, 2020 2 Table S1. Hazard ratios for patients treated in Hubei estimated by multivariate proportional hazard Cox model Variables HR LL UL P value Age (continuous) 1.036 1.021 1.05 <0.001 Any comorbidity (yes vs. no) 2.095 1.419 3.093 <0.001 Hubei location (yes vs. no) 1.594 1.054 2.412 0.027 HR: hazards ratio; LL: lower limit of the 95% confidence interval; UL: upper limit of the 95% confidence interval Table S2. Hazard ratios for Wuhan-contacts estimated by multivariate proportional hazard Cox model Variables HR LL UL P value Age (continuous) 1.039 1.025 1.053 <0.001 Any comorbidity (yes vs.
    [Show full text]
  • Esophageal and Gastric Cancer
    ESOPHAGEAL AND GASTRIC CANCER 159 Oral Abstract Session Confirmed three-year RFS and OS of the randomized trial of adjuvant S-1 versus S-1 plus docetaxel after curative resection of pStage III gastric cancer (JACCRO GC-07). Kazuhiro Yoshida, Yasuhiro Kodera, Mitsugu Kochi, Takeshi Sano, Yoshihiro Kakeji, Wataru Ichikawa, Shintaro Kurahashi, Hironori Yamaguchi, Takahiro Toyokawa, Masato Nakamura, Kazumasa Fujitani, Yoshinari Mochizuki, Mitsuhiko Ota, Jun Hihara, Yoichi Makari, Atsushi Takeno, Masahiro Takeuchi, Masashi Fujii; Department of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu, Japan; Nagoya University Graduate School of Medicine, Gastroenterological Surgery, Nagoya, Japan; Department of Digestive Surgery, Nihon University Itabashi Hospital, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Division of Gastrointestinal Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan; Division of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, Japan; Department of Gastroenterological Surgery, Aichi Medical University, Nagakute, Japan; Jichi Medical University, Tochigi, Japan; Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan; Aizawa Comprehensive Cancer Center, Aizawa Hospital, Matsumoto, Japan; Department of Surgery, Osaka General Medical Center, Osaka, Japan; Komaki Municipal Hospital, Komaki, Japan; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan;
    [Show full text]
  • Clinical Characteristics and Outcomes of Hospitalised Patients with COVID-19 Treated in Hubei
    Early View Original article Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non- epicenter): A Nationwide Analysis of China Wen-hua Liang, Wei-jie Guan, Cai-chen Li, Yi-min Li, Heng-rui Liang, Yi Zhao, Xiao-qing Liu, Ling Sang, Ru-chong Chen, Chun-li Tang, Tao Wang, Wei Wang, Qi-hua He, Zi-sheng Chen, Sook-San Wong, Mark Zanin, Jun Liu, Xin Xu, Jun Huang, Jian-fu Li, Li-min Ou, Bo Cheng, Shan Xiong, Zhan- hong Xie, Zheng-yi Ni, Yu Hu, Lei Liu, Hong Shan, Chun-liang Lei, Yi-xiang Peng, Li Wei, Yong Liu, Ya-hua Hu, Peng Peng, Jian-ming Wang, Ji-yang Liu, Zhong Chen, Gang Li, Zhi-jian Zheng, Shao-qin Qiu, Jie Luo, Chang-jiang Ye, Shao-yong Zhu, Lin-ling Cheng, Feng Ye, Shi-yue Li, Jin-ping Zheng, Nuo-fu Zhang, Nan-shan Zhong, Jian-xing He Please cite this article as: Liang W-hua, Guan W-jie, Li C-chen, et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): A Nationwide Analysis of China. Eur Respir J 2020; in press (https://doi.org/10.1183/13993003.00562-2020). This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.
    [Show full text]
  • 1 Please Read These Instructions Carefully
    PLEASE READ THESE INSTRUCTIONS CAREFULLY. MISTAKES IN YOUR CSC APPLICATION COULD LEAD TO YOUR APPLICATION BEING REJECTED. Visit http://studyinchina.csc.edu.cn/#/login to CREATE AN ACCOUNT. • The online application works best with Firefox or Internet Explorer (11.0). Menu selection functions may not work with other browsers. • The online application is only available in Chinese and English. 1 • Please read this page carefully before clicking on the “Application online” tab to start your application. 2 • The Program Category is Type B. • The Agency No. matches the university you will be attending. See Appendix A for a list of the Chinese university agency numbers. • Use the + by each section to expand on that section of the form. 3 • Fill out your personal information accurately. o Make sure to have a valid passport at the time of your application. o Use the name and date of birth that are on your passport. Use the name on your passport for all correspondences with the CLIC office or Chinese institutions. o List Canadian as your Nationality, even if you have dual citizenship. Only Canadian citizens are eligible for CLIC support. o Enter the mailing address for where you want your admission documents to be sent under Permanent Address. Leave Current Address blank. Contact your home or host university coordinator to find out when you will receive your admission documents. Contact information for you home university CLIC liaison can be found here: http://clicstudyinchina.com/contact-us/ 4 • Fill out your Education and Employment History accurately. o For Highest Education enter your current degree studies.
    [Show full text]
  • THE TANCI FICTION JING ZHONG ZHUAN by YU ZHANG A
    THE FEMALE REWRITING OF GRAND HISTORY: THE TANCI FICTION JING ZHONG ZHUAN by YU ZHANG A DISSERTATION Presented to the Department of East Asian Languages and Literatures and the Graduate School of the University of Oregon in partial fulfillment of the requirements for the degree of Doctor of Philosophy June 2013 DISSERTATION APPROVAL PAGE Student: Yu Zhang Title: The Female Rewriting of Grand History: The Tanci Fiction Jing zhong zhuan This dissertation has been accepted and approved in partial fulfillment of the requirements for the Doctor of Philosophy degree in the Department of East Asian Languages and Literatures by: Maram Epstein Chairperson Tze-lan Sang Core Member Yugen Wang Core Member Bryna Goodman Institutional Representative and Kimberly Andrews Espy Vice President for Research and Innovation; Dean of the Graduate School Original approval signatures are on file with the University of Oregon Graduate School. Degree awarded June 2013 ii © 2013 Yu Zhang iii DISSERTATION ABSTRACT Yu Zhang Doctor of Philosophy Department of East Asian Languages and Literatures June 2013 Title: The Female Rewriting of Grand History: The Tanci Fiction Jing zhong zhuan This dissertation has examined the tanci fiction Jing zhong zhuan, or A Biography of Dedication and Loyalty, authored by a gentry woman writer Zhou Yingfang in the late nineteenth century. I argue that by adapting the well-known patriotic story of General Yue Fei in Chinese history, Zhou Yingfang suggests new directions in grand historical narrative in her own voice and from her own perspective. Negotiating the writing conventions of earlier legends, she turns the stereotyped masculine image of Yue Fei into a hero in both public and domestic settings.
    [Show full text]
  • Dietary Chinese Herbs Yanze Liu • Zhimin Wang Junzeng Zhang Editors
    Dietary Chinese Herbs Yanze Liu • Zhimin Wang Junzeng Zhang Editors Dietary Chinese Herbs Chemistry, Pharmacology and Clinical Evidence 123 Editors Yanze Liu Junzeng Zhang Institute of Medicinal Plant Development Aquatic and Crop Resource Development Chinese Academy of Medical Sciences National Research Council of Canada and Peking Union Medical College Halifax Beijing Canada China Zhimin Wang Institute of Chinese Materia Medica China Academy of Chinese Medical Sciences Beijing China ISBN 978-3-211-99447-4 ISBN 978-3-211-99448-1 (eBook) DOI 10.1007/978-3-211-99448-1 Library of Congress Control Number: 2015934051 Springer Wien Heidelberg New York Dordrecht London © Springer-Verlag Wien 2015 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.
    [Show full text]
  • Radiology of Infectious Diseases: Volume 2
    Radiology of Infectious Diseases: Volume 2 Hongjun Li Editor Radiology of Infectious Diseases: Volume 2 Editor Hongjun Li Beijing You An Hospital Capital Medical University Diagnostic Radiology Department Beijing China ISBN 978-94-017-9875-4 ISBN 978-94-017-9876-1 (eBook) DOI 10.1007/978-94-017-9876-1 Library of Congress Control Number: 2015943785 Springer Dordrecht Heidelberg New York London © Springer Science+Business Media Dordrecht and People's Medical Publishing House 2015 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfi lms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specifi c statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. Printed on acid-free paper Springer Science+Business Media B.V.
    [Show full text]